We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




U.S. Plans Production of Medical Isotopes in 2018

By MedImaging International staff writers
Posted on 26 Apr 2017
Print article
Image: The University of Missouri Research Reactor (Photo courtesy of MURR).
Image: The University of Missouri Research Reactor (Photo courtesy of MURR).
Once operational, the University of Missouri Research Reactor will be capable of supporting nearly half of U.S. demand for molybdenum-99 (Mo-99), which currently must be imported from outside North America.

MURR and its partners Nordion and General Atomics have announced that MURR’s license amendment request (LAR) has been submitted to the U.S. Nuclear Regulatory Commission, a critical step towards implementing domestic U.S. production of Mo-99. Once approved, MURR will begin producing Mo-99 using selective gaseous extraction (SGE), a proprietary technology developed by GA to extract the isotope from low enriched uranium targets.

The patented approach will produce Mo-99 of high specific activity, while avoiding the production of liquid uranium waste, a significant problem with existing technologies that require highly enriched uranium (HEU). The extracted Mo-99 will be sent to Nordion for final purification and distribution to radiopharmaceutical manufacturers, after which it will be distributed to hospitals and medical facilities around the world. Nordion will continue to maintain its conventional Mo-99 processing capacity through March 31, 2018, in the event of a significant global shortage of Mo-99.

“This LAR submission shows the Nuclear Regulatory Commission that we will have all of the technology, expertise, and safety measures needed to begin producing Mo-99 in place and ready to go once approval has been received,” said Ralph Butler, executive director of MURR. “As a public research institution, we are proud to play a partnership role with GA and Nordion in helping America secure a new, domestic source of Mo-99.”

The most important medical isotope, technetium-99m (Tc-99m), is obtained from the decay of its parent Mo-99, and is used in more than 80% of all nuclear medicine procedures. Mo-99 is packed into source containment vessels and distributed to hospitals, where nuclear medicine specialists can draw off the Tc-99m as needed for about a week. Because of its unstable nature, Mo-99 does not occur naturally and is traditionally produced using HEU in research reactors in Canada, the Netherlands, Belgium, France, Australia, and South Africa.

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Crossover Angiography System
Trinias C16/C12/F12 Unity Smart Edition
New
DR Flat Panel Detector
1500L
New
Ultrasound Needle Guide
Ultra-Pro II

Print article

Channels

Ultrasound

view channel
Image: Structure of the proposed transparent ultrasound transducer and its optical transmittance (Photo courtesy of POSTECH)

Ultrasensitive Broadband Transparent Ultrasound Transducer Enhances Medical Diagnosis

The ultrasound-photoacoustic dual-modal imaging system combines molecular imaging contrast with ultrasound imaging. It can display molecular and structural details inside the body in real time without... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The acquisition will expand IBA’s medical imaging quality assurance offering (Photo courtesy of Radcal)

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

Ion Beam Applications S.A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.